Marker Therapeutics (MRKR) shares surged 11% after winning a $9.5M grant for clinical investigation of MT-601 in pancreatic ...

Immuno-oncology company Marker Therapeutics, Inc. (MRKR) announced Tuesday that the Company has been awarded a $9.5 million grant ...

Marker Therapeutics (MRKR) announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute ...

Marker Therapeutics (NASDAQ:MRKR) just reported results for the fourth quarter of 2023. Marker Therapeutics reported earnings per share of -30 cents. The company reported revenue of $1.06 million.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product ...

Detailed price information for Marker Therapeutics Inc (MRKR-Q) from The Globe and Mail including charting and trades.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Marker Therapeutics Inc (NASDAQ:MRKR) decreased during the last reporting period, falling from 70.00K to 56.99K. This put 0.88% of the company's publicly available shares short.